The objective of this study is to investigate the efficacy of a nurse-led prednisolone tapering regime in patients with polymyalgia rheumatica (PMR) compared to standard care. It is a single-center retrospective cohort study evaluating dose and percentage of patients receiving prednisolone after 1 and 2 years. A nurse-led PMR clinic was introduced June 2015 and patients diagnosed until June 2017 were included. Patients were diagnosed by a rheumatologist, and subsequently managed by nurses according to a specific protocol. Patients diagnosed with PMR between June 2012 and June 2015 served as controls. They received standard care by a rheumatologist. Sixty-eight patients received standard care and 107 nurse-led care. After 1 year, 71% of patients receiving standard care vs. 64% receiving nurse-led care took prednisolone (p = 0.441). Median (interquartile range) prednisolone dose after 1 year was 3.75 mg (0–5) in the standard care group and 1.25 mg (0–3.75) in the nurse-led care group (p = 0.004). After 2 years, 41% of patients receiving standard care vs. 18% receiving nurse-led care took prednisolone (p = 0.003). Prednisolone dose after 2 years was 0 mg (0–2.5) in the standard care group and 0 mg (0–0) in the nurse-led care group (p = 0.004). There was no difference regarding relapse and initiation of methotrexate. The number of patient contacts was 12.5 (5–16.5) in the standard care group vs. 17 (13–23) in the nurse-led care group (p = 0.001). A tight and systematic approach to prednisolone tapering is more effective than standard care, but more frequent patient contacts were necessary to obtain this effect.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, Cimmino M, Gerli R, Catanoso MG, Boiardi L, Cantini F, Klersy C, Hunder GG (2007) Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146(9):631–639
Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, Montecucco C, Systemic Vasculitis Study Group of the Italian Society for R (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141(7):493–500
Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E (1996) Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 23(4):624–628
van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55(4):218–223
Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG (1997) Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40(10):1873–1878
Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48(8):658–661
Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, Abril A, Bachta A, Balint P, Barraclough K, Bianconi L, Buttgereit F, Carsons S, Ching D, Cid M, Cimmino M, Diamantopoulos A, Docken W, Duftner C, Fashanu B, Gilbert K, Hildreth P, Hollywood J, Jayne D, Lima M, Maharaj A, Mallen C, Martinez-Taboada V, Maz M, Merry S, Miller J, Mori S, Neill L, Nordborg E, Nott J, Padbury H, Pease C, Salvarani C, Schirmer M, Schmidt W, Spiera R, Tronnier D, Wagner A, Whitlock M, Matteson EL, Dasgupta B, European League Against R, American College of R (2015) 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799–1807. https://doi.org/10.1136/annrheumdis-2015-207492
Muratore F, Pipitone N, Hunder GG, Salvarani C (2013) Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 31(4 Suppl 78):S86–92
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. https://doi.org/10.1016/j.jbi.2008.08.010
Dasgupta B, Dolan AL, Panayi GS, Fernandes L (1998) An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 37(2):189–195
Pelechas E, Voulgari PV, Drosos AA (2019) Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 15:1073–1079. https://doi.org/10.2147/tcrm.S167452
Ayoub WT, Franklin CM, Torretti D (1985) Polymyalgia rheumatic. Duration of therapy and long-term outcome. Am J Med 79(3):309–315. https://doi.org/10.1016/0002-9343(85)90309-2
Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159(6):577–584
Bahlas S, Ramos-Remus C, Davis P (1998) Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 25(1):99–104
Myklebust G, Gran JT (2001) Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 30(5):260–267
Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D (1999) Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 26(9):1945–1952
Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52(12):847–850
Lundberg I, Hedfors E (1990) Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 17(10):1340–1345
Smolen JS (2019) Treat to target in rheumatology: a historical account on occasion of the 10th anniversary. Rheum Dis Clin N Am 45(4):477–485. https://doi.org/10.1016/j.rdc.2019.07.001
Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–269. https://doi.org/10.1016/s0140-6736(04)16676-2
Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M (2017) Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study. Rheumatology (Oxford) 56(4):529–533. https://doi.org/10.1093/rheumatology/kew395
Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R, Rees F, Stevenson M, Zhang W (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet (London, England) 392(10156):1403–1412. https://doi.org/10.1016/S0140-6736(18)32158-5
Borresen SW, Thorgrimsen TB, Jensen B, Hilsted L, Bartels EM, Feldt-Rasmussen U, Locht H (2020) Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keaa011
van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39(12):1383–1389. https://doi.org/10.1093/rheumatology/39.12.1383
Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J (1994) Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154(1):97–101
The authors are grateful for the excellent help of Andrew Bolas with data management.
No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.
Conflict of interest
All authors report no conflicts of interest.
The study was approved by the Danish Data Protection Agency (case number 1-16-02-295-18, approval date 30.10.2018) and the Danish Patient Safety Authority (case number 3-3013-2689/1, approval date 22.06.2018).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Congress abstracts: This work has been published as an abstract for the EULAR 2020 congress (Ann Rheum Dis, volume 79, supplement 1, year 2020, page 859).
About this article
Cite this article
Mørk, C., Dam, M.Y., Callsen, M.G. et al. The effect of a nurse-led prednisolone tapering regimen in polymyalgia rheumatica: a retrospective cohort study. Rheumatol Int 41, 605–610 (2021). https://doi.org/10.1007/s00296-020-04654-w
- Polymyalgia rheumatica
- Nurse-led care
- Tapering regimen